SCHEMBL3762383

SCHEMBL3762383

CCOC(=O)CNC(=O)c1c(OC)ccc2cc(-c3ccccc3)cnc12

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.57
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.43
PDGFRB P09619 2/20 0.42
PDGFRA P16234 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
EGLN1 Q9GZT9 2/20 0.41
VEGFA P15692 1/20 0.41
FLT1 P17948 1/20 0.41
ALDH1A1 P00352 4/20 0.40
LMNA P02545 2/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
STAMBP O95630 1/20 0.39
MAPT P10636 1/20 0.39
PPID Q08752 1/20 0.39
P2RY12 Q9H244 1/20 0.39
GLA P06280 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760876 0.82 EGLN3 (0.54) EGLN3HPGDHSD17B10EGLN1VEGFA
SCHEMBL3758192 0.81 HPGD (0.47) HPGDHSD17B10SMN1; SMN2EGLN1ALDH1A1
SCHEMBL3755178 0.79 PDGFRB (0.52) EGLN3PDGFRBPDGFRAMAPT
SCHEMBL3396850 0.73 EGLN3 (1.00) EGLN3EGLN1VEGFAFLT1
SCHEMBL1165214 0.73 EGLN3 (0.59) EGLN3HPGDHSD17B10SMN1; SMN2EGLN1
SCHEMBL1165232 0.72 SMN1; SMN2 (0.43) HPGDHSD17B10SMN1; SMN2EGLN1ALDH1A1
SCHEMBL70720 0.72 EGLN1 (0.62) HPGDEGLN1ALDH1A1LMNAMAPT
SCHEMBL3752845 0.72 EGLN3 (0.42) EGLN3HPGDHSD17B10SMN1; SMN2EGLN1
SCHEMBL3518478 0.71 EGLN3 (0.50) EGLN3HPGDHSD17B10SMN1; SMN2EGLN1
SCHEMBL3518821 0.71 EGLN3 (0.49) EGLN3HPGDHSD17B10SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305154-A1 Prolyl Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305154-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885HPGD 58/4885HSD17B10 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.